Cartalax

an identity-gated Ala-Glu-Asp tripeptide with cell and animal work plus one poorly reported, 29-person saline-controlled human example in an assignee patent, but no independent peer-reviewed replication or measured pharmacokinetic curve.

tier C · healing · 29 people in patent Example 5

verdict

the exact AED tripeptide has a real chemical identity, preclinical signals, and one sparse assignee-patent human signal, but the consequential claims remain behind weak reporting, absent independent replication, and a product-identity gate.

if you're asking what Cartalax actually is — this record is for the synthetic tripeptide L-Ala-L-Glu-L-Asp, abbreviated AED or T-31. it is not a cartilage extract, not an unspecified polypeptide complex, and not the different short peptides AEDP or AEDG.

if you're asking whether it repairs human cartilage or joints — Example 5 of WO2007139433A1 describes 29 people aged 52 to 72 with knee osteoarthrosis, says they were randomly divided, and identifies 12 saline controls. the assignee reports pain and movement changes, but does not provide active-subgroup sizes, clear blinding or attrition reporting, adequate group-level control comparisons, adverse-event detail, or an independently peer-reviewed replication. it does not establish cartilage repair.

if you're asking what its half-life is — unknown. no human or animal concentration-time study reporting an elimination half-life was located. a tissue effect reported after dosing and a peptide's small size are not substitutes for a measured curve.

if you're asking whether repeated animal dosing proves it is safe — no. the repeated-dose claims come from a patent written by the assignee, with no independent peer-reviewed toxicology report located. its 29-person human example also lacks adequate adverse-event and safety reporting. the examples remain useful as a record of what was administered, but they do not establish human safety.

animal and human patent evidence is labeled at the point of use. patent-reported amounts are not dosing guidance or a validated protocol, and animal exposures are not converted into human-equivalent doses.

why C-tier

C-tier applies only to identity-verified synthetic L-Ala-L-Glu-L-Asp. The molecule is defined, has cell and animal observations, and has sparse human evidence in a poorly reported 29-person saline-controlled assignee-patent example. It cannot grade higher because the patent omits important design, group-level outcome, and safety detail; no independent peer-reviewed replication, formal pharmacokinetic study, independent toxicology package, or regulator-reviewed product was located. A product with unresolved sequence or extract composition does not inherit this grade.

the core tension

Exact synthetic AED is a defined 333.29 Da tripeptide with cell findings and a sparse 29-person saline-controlled human example in an assignee patent. The name Cartalax also circulates around compositionally different products, while poor patent reporting, absent independent peer-reviewed replication, and missing pharmacokinetics leave the joint and safety claims unresolved.

what it is

The synthetic test article is L-alanyl-L-glutamyl-L-aspartic acid, AED, a 333.29 Da tripeptide with CAS 85806-95-7. That identity is defined by sequence, stereochemistry, free termini, and any declared salt or counterion. A retail name alone cannot distinguish it from cartilage-derived peptide complexes sold under similar language.

what it does

AED has been studied at nanomolar concentrations in aging human mesenchymal stem-cell and skin-fibroblast cultures. Those studies reported changes in gene-expression and cell-state markers. The patent adds ex-vivo cartilage observations, animal toxicity and morphology examples, and Example 5: a 29-person knee-osteoarthrosis example with 12 saline controls and assignee-reported pain and movement changes. That human example is too poorly reported to establish cartilage repair, a reliable joint benefit, or safety.

origin

The exact sequence appears in the Khavinson short-peptide literature and in patent WO2007139433A1. The patent supplies most of the in-vivo dosing record, including the only located human administration example. Patent disclosure can establish what an assignee says it administered; it does not provide the independent review, adverse-event capture, transparent group-level reporting, or replication of a clinical development dossier.

why researchers are interested

Three amino acids make the tissue-repair story look simple and the market story sound precise. The actual evidence is narrower: cell-culture gene-expression changes, patent-reported cartilage and animal observations, and one poorly reported saline-controlled human example. The main practical uncertainty is whether a product labeled Cartalax contains the exact synthetic AED molecule reviewed here.

does it work

A sparse human joint signal is claimed in one assignee patent, not established in independent clinical literature. C-tier applies to identity-verified synthetic AED because the molecule, cell findings, and 29-person saline-controlled patent example are real evidence, while poor reporting and absent independent peer-reviewed replication keep confidence low. If product identity is not verified, the molecule-level grade does not transfer and the product fails the identity threshold.

claims vs the data

• Cartalax is always the synthetic AED tripeptide — unsupported — market descriptions also use the name for cartilage-derived peptide or polypeptide complexes. exact sequence and composition must be verified.
• AED changes aging-related cell markers — preclinical — published human cell-culture studies report gene-expression and cell-state changes at nanomolar concentrations. they are not clinical outcomes.
• Cartalax repairs human cartilage — unsupported — the 29-person assignee-patent example claims pain and movement changes but reports no significant radiographic dynamics, lacks adequate group-level detail, and has no located independent peer-reviewed replication. it does not demonstrate cartilage repair.
• repeated animal dosing proves long-term safety — unsupported — the repeated-dose reports are assignee patent examples without an independent peer-reviewed toxicology paper.
• Cartalax has a known short half-life — unsupported — no measured human or animal concentration-time half-life was located. peptide size alone cannot supply the number.

key facts

• molecular formula: C12H19N3O8
• molecular weight: 333.29 g/mol
• amino acids: 3
• half-life: unknown; no measured concentration-time half-life
• type: synthetic acidic tripeptide; identity-gated
• CAS: 85806-95-7
• 3 aa exact synthetic AED sequence
• 29 people in assignee-patent Example 5
• 12 saline controls described in the patent
• 0 measured PK studies

frequently asked questions

What is Cartalax?

For this page, Cartalax means the exact synthetic tripeptide L-Ala-L-Glu-L-Asp, also called AED or T-31. Cartilage extracts and unspecified peptide complexes are different test articles.

Is Cartalax the same as AEDG or AEDP?

No. AED, AEDG, and AEDP are different amino-acid sequences. Evidence cannot be transferred between them by name similarity.

Does Cartalax repair cartilage?

The assignee patent's Example 5 describes 29 people with knee osteoarthrosis, including 12 saline controls, and claims pain and movement improvements. Reporting is too sparse to establish a reliable joint effect, it reports no significant radiographic dynamics during the period, and no independent peer-reviewed replication was located. The example does not prove cartilage repair.

What is the half-life of Cartalax?

Unknown. No concentration-time study reporting a human or animal elimination half-life was located. The page does not infer one from peptide size or a reported tissue effect.

Is Cartalax safe?

Human safety is not established. Repeated-dose animal claims come from an assignee patent rather than an independent toxicology publication. Injectable products also carry identity, sterility, endotoxin, impurity, and concentration risks.

Is Cartalax approved?

No FDA, EMA, or national drug approval was located for exact synthetic AED. Retail availability or use of a product name does not establish approved-drug status.

related peptides

• bpc-157 — a separate tissue-repair dossier whose evidence cannot be transferred to AED
• tb-500 — a distinct tissue-repair research peptide with its own identity and evidence file
• ghk-cu — a different peptide class used in tissue-repair comparisons

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.